Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Recent studies from Baylor University add new data to adenocarcinoma
July 29th, 2008
According to recent research from the United States, "Preclinical studies using sequences of topoisomerase I and II inhibitors suggested synergism; preliminary clinical studies, resulting in enhanced antitumor responses, confirm this in selected malignancies. This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract." "Correlation of topoisomerase II beta was also done. Eligibility criteria in included the following: documented adenocarcinoma of the lung, breast, or gastrointestinal tract, < 3 prior...
Source: Cancer Weekly (2008-07-29)
|
